CL2014000441A1 - Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. - Google Patents
Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.Info
- Publication number
- CL2014000441A1 CL2014000441A1 CL2014000441A CL2014000441A CL2014000441A1 CL 2014000441 A1 CL2014000441 A1 CL 2014000441A1 CL 2014000441 A CL2014000441 A CL 2014000441A CL 2014000441 A CL2014000441 A CL 2014000441A CL 2014000441 A1 CL2014000441 A1 CL 2014000441A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- nedd
- hydroxycyclopentyl
- inden
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526830P | 2011-08-24 | 2011-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000441A1 true CL2014000441A1 (es) | 2014-09-26 |
Family
ID=47747080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000441A CL2014000441A1 (es) | 2011-08-24 | 2014-02-24 | Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8809356B2 (OSRAM) |
| EP (2) | EP3323414A1 (OSRAM) |
| JP (1) | JP6038150B2 (OSRAM) |
| KR (1) | KR20140054288A (OSRAM) |
| CN (1) | CN103889988B (OSRAM) |
| AR (1) | AR087672A1 (OSRAM) |
| AU (1) | AU2012298813B2 (OSRAM) |
| BR (1) | BR112014004239A2 (OSRAM) |
| CA (1) | CA2846231C (OSRAM) |
| CL (1) | CL2014000441A1 (OSRAM) |
| CO (1) | CO6900148A2 (OSRAM) |
| CR (1) | CR20140128A (OSRAM) |
| DO (1) | DOP2014000037A (OSRAM) |
| EA (1) | EA031067B1 (OSRAM) |
| EC (1) | ECSP14013263A (OSRAM) |
| GE (1) | GEP201606522B (OSRAM) |
| HK (1) | HK1199252A1 (OSRAM) |
| IL (1) | IL231069B (OSRAM) |
| MA (1) | MA35439B1 (OSRAM) |
| MX (1) | MX2014002015A (OSRAM) |
| MY (1) | MY166889A (OSRAM) |
| PE (1) | PE20141146A1 (OSRAM) |
| PH (1) | PH12014500419A1 (OSRAM) |
| SG (2) | SG11201400102WA (OSRAM) |
| TN (1) | TN2014000080A1 (OSRAM) |
| TW (1) | TWI577667B (OSRAM) |
| UA (1) | UA114894C2 (OSRAM) |
| UY (1) | UY34292A (OSRAM) |
| WO (1) | WO2013028832A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| PH12014500419A1 (en) * | 2011-08-24 | 2020-06-22 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| UA116534C2 (uk) | 2012-02-17 | 2018-04-10 | Мілленніум Фармасьютікалз, Інк. | Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту |
| WO2014022744A1 (en) | 2012-08-03 | 2014-02-06 | Millennium Pharmaceuticals, Inc. | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| CA2916468C (en) * | 2013-07-02 | 2019-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| CN103948590A (zh) * | 2014-05-22 | 2014-07-30 | 中国药科大学 | Nedd8激活酶抑制剂及其医药用途 |
| NZ728162A (en) * | 2014-07-01 | 2023-06-30 | Takeda Pharmaceuticals Co | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| KR101927375B1 (ko) * | 2016-04-20 | 2018-12-11 | 한국화학연구원 | 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2018213258A1 (en) * | 2017-05-15 | 2018-11-22 | Millennium Pharmaceuticals, Inc. | Treatment of merlin-deficient tumors using nae inhibitors |
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| WO2023025668A1 (en) | 2021-08-25 | 2023-03-02 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for the generation of stem cell memory t cells for adoptive t cell therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194446A (en) | 1989-06-12 | 1993-03-16 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals |
| WO1997005132A1 (en) | 1995-07-28 | 1997-02-13 | Cubist Pharmaceuticals, Inc. | Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents |
| WO2004043955A1 (en) | 2002-11-13 | 2004-05-27 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
| WO2005037845A1 (en) | 2003-10-17 | 2005-04-28 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors |
| WO2006002284A1 (en) | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| SI1848718T1 (sl) | 2005-02-04 | 2012-12-31 | Millennium Pharmaceuticals, Inc. | Inhibitorji E1 aktivacijskih enzimov |
| JP5231251B2 (ja) * | 2006-02-02 | 2013-07-10 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｅ１活性化酵素の阻害剤 |
| CA2659894C (en) * | 2006-08-08 | 2018-03-27 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| BRPI1012142A2 (pt) * | 2009-05-14 | 2016-03-29 | Millennium Pharm Inc | sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato |
| PH12014500419A1 (en) * | 2011-08-24 | 2020-06-22 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| MY176125A (en) * | 2011-11-03 | 2020-07-24 | Takeda Pharmaceuticals Co | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent |
-
2012
- 2012-08-23 PH PH1/2014/500419A patent/PH12014500419A1/en unknown
- 2012-08-23 EA EA201400249A patent/EA031067B1/ru not_active IP Right Cessation
- 2012-08-23 US US13/592,389 patent/US8809356B2/en active Active
- 2012-08-23 WO PCT/US2012/052007 patent/WO2013028832A2/en not_active Ceased
- 2012-08-23 SG SG11201400102WA patent/SG11201400102WA/en unknown
- 2012-08-23 CN CN201280052013.2A patent/CN103889988B/zh not_active Expired - Fee Related
- 2012-08-23 BR BR112014004239A patent/BR112014004239A2/pt not_active Application Discontinuation
- 2012-08-23 UA UAA201402893A patent/UA114894C2/uk unknown
- 2012-08-23 PE PE2014000250A patent/PE20141146A1/es active IP Right Grant
- 2012-08-23 HK HK14112794.7A patent/HK1199252A1/xx unknown
- 2012-08-23 JP JP2014527287A patent/JP6038150B2/ja not_active Expired - Fee Related
- 2012-08-23 KR KR1020147007200A patent/KR20140054288A/ko not_active Abandoned
- 2012-08-23 EP EP17193006.8A patent/EP3323414A1/en not_active Withdrawn
- 2012-08-23 EP EP12825411.7A patent/EP2748168A4/en not_active Withdrawn
- 2012-08-23 MY MYPI2014000482A patent/MY166889A/en unknown
- 2012-08-23 GE GEAP201213424A patent/GEP201606522B/en unknown
- 2012-08-23 SG SG10201601023UA patent/SG10201601023UA/en unknown
- 2012-08-23 MX MX2014002015A patent/MX2014002015A/es unknown
- 2012-08-23 CA CA2846231A patent/CA2846231C/en not_active Expired - Fee Related
- 2012-08-23 AU AU2012298813A patent/AU2012298813B2/en not_active Ceased
- 2012-08-24 TW TW101130884A patent/TWI577667B/zh not_active IP Right Cessation
- 2012-08-24 UY UY0001034292A patent/UY34292A/es not_active Application Discontinuation
- 2012-08-24 AR ARP120103134A patent/AR087672A1/es unknown
-
2014
- 2014-02-20 IL IL231069A patent/IL231069B/en active IP Right Grant
- 2014-02-21 TN TNP2014000080A patent/TN2014000080A1/en unknown
- 2014-02-24 CL CL2014000441A patent/CL2014000441A1/es unknown
- 2014-02-24 DO DO2014000037A patent/DOP2014000037A/es unknown
- 2014-03-12 CO CO14052377A patent/CO6900148A2/es unknown
- 2014-03-13 MA MA36826A patent/MA35439B1/fr unknown
- 2014-03-17 CR CR20140128A patent/CR20140128A/es unknown
- 2014-03-21 EC ECSP14013263 patent/ECSP14013263A/es unknown
- 2014-07-08 US US14/326,051 patent/US9850214B2/en active Active
-
2017
- 2017-11-09 US US15/808,491 patent/US20180290983A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000441A1 (es) | Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. | |
| CY1125155T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| BR112015000399A2 (pt) | derivados de pirazolil pirimidina | |
| WO2014031872A3 (en) | Small molecule inhibitors for treating parasitic infections | |
| CU20110027A7 (es) | Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap) | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
| MX2013013294A (es) | Inhibidores de tirosina-cinasas. | |
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| BR112013019223A2 (pt) | forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral | |
| PH12015500260A1 (en) | Neprilysin inhibitors | |
| UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
| ECSP14013179A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| MX2012006233A (es) | Nuevos compuestos de espiropiperidina. | |
| EA201270280A1 (ru) | Соединения пиримидина в качестве ингибиторов при лечении туберкулеза | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
| CL2011000292A1 (es) | Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| BR112013025236A2 (pt) | derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia | |
| CL2008002892A1 (es) | Procedimiento de preparacion de sales quirales de esteres de (1r,5s)-anhidroecgonina sustituida. | |
| BR112013009176A2 (pt) | processo para a síntese de álcoois quirais propargílicos. | |
| MX2010006218A (es) | Compuestos organicos. | |
| MX2013002656A (es) | Nuevo proceso. | |
| CU24258B1 (es) | Sales de 3-3-carboxi-n-etil-n,n-dimetilpropan-1-aminio útiles en el tratamiento de enfermedades cardiovasculares |